Form 8-K Intellia Therapeutics, For: Aug 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Cowen on Intellia Therapeutics (NTLA): 'We continue to view NTLA as a leader in the gene editing space'
August 4, 2022 11:06 AM EDTCowen analyst Joseph Thome reiterated an Outperform rating and {REMOVEPT} price target on Intellia Therapeutics (NASDAQ: NTLA)
The analyst comments "NTLA remains on track to present initial data from NTLA-2001 in ATTR-CM and NTLA-2002 in HAE in H2:22. The... More
RBC Capital on Intellia Therapeutics (NTLA) as Shares Like Over 10%: 'Stock Reaction Overdone'
August 4, 2022 10:17 AM EDTRBC Capital analyst Luca Issi reiterated an Outperform rating and $150.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "NTLA announced today a new case of possibly drug-related liver enzyme elevation at 1 mg/kg and is backing off the dose going forward from... More
